CompletedNCT00636818
Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)
Medication studyAges 18+Multiple countries
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Beijing and 10 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateMarch 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 45
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- China, South Korea, Taiwan
- Age range
- Over 18 Years
- Official registry ID
- NCT00636818
- Official title
Show the full official title
An Open Study of Atomoxetine (LY139603) in Adult Subjects With Attention-deficit/Hyperactivity Disorder
Recruitment & locations
CompletedBeijing, China · Changsha, China · Guangzhou, China
8 more locations
- Busan, South Korea
- Incheon, South Korea
- Jeonju, South Korea
- Seoul, South Korea
- Neihu Taipei, Taiwan
- Niao Sung Hsiang, Taiwan
- Taipei, Taiwan
- Taoyuan, Taiwan
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine.
Who was this study for?
This study was for people with ADHD. Listed age limits: from 18 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants
A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine